Q-square (Q2) is a global Clinical Research Organization (CRO) providing a broad range of clinical services for pharmaceutical and biotechnology partners since 2009. Q2 team has experienced over 900 studies and 26 successful NDA/BLA submissions in various therapeutic areas. Q2 is a pioneer in adopting CDISC and Q2 team supported the world first FDA Project ORBIS. Mission - to be the most cost-effective and innovative global leader in providing services in excellent quality and most reliable solutions to speed up drug development and reduce cost for pharmaceutical/biotechnology companies and to shorten the time for patients to receive medicines. Vision - to be the best-in-class provider of clinical development services to the pharmaceutical industry through broad therapeutic and geographic expertise to create a win-win situation for our partners. Client and Service - Q2 has been committed to providing the best services in the following areas: • EDC and IWRS/IRT Service • Clinical Data Management • CDISC Services (SDTM, ADaM, define.xml, Study Data Reviewers Guide (SDRG), ADRG, Pinnacle 21) • Biostatistics and Programming (Study designs, SAP, TFLs, DMC/DSMB, ISS, ISE, Ad hoc) • Drug safety & Pharmacovigilance Q2 has clients from small and mid-size to large size companies, from pharmaceutical to medical device companies, from North America, Europe to Asia, covering from phase I to post-marketing studies.